Man Group plc Has $15.21 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Man Group plc increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 359.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 82,390 shares of the medical research company's stock after purchasing an additional 64,456 shares during the period. Man Group plc owned approximately 0.16% of Charles River Laboratories International worth $15,209,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Veracity Capital LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $589,000. Allspring Global Investments Holdings LLC raised its stake in shares of Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after buying an additional 47,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Charles River Laboratories International by 46.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after purchasing an additional 1,679 shares during the period. Boston Trust Walden Corp boosted its stake in Charles River Laboratories International by 4.3% in the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after buying an additional 8,338 shares in the last quarter. Finally, E. Ohman J or Asset Management AB grew its position in Charles River Laboratories International by 225.0% in the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after acquiring an additional 1,800 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on CRL shares. Barclays lifted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $172.31.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 5,040 shares of company stock worth $807,407. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 5.9%

Shares of Charles River Laboratories International stock traded down $8.52 on Wednesday, hitting $135.01. 825,476 shares of the company's stock traded hands, compared to its average volume of 983,282. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The firm's 50-day moving average price is $134.37 and its two-hundred day moving average price is $164.34. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market capitalization of $6.63 billion, a PE ratio of 900.08, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.27 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).